Adoptive cell therapy for the treatment of patients with metastatic melanoma - PubMed (original) (raw)
Review
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Steven A Rosenberg et al. Curr Opin Immunol. 2009 Apr.
Abstract
Adoptive cell therapy (ACT) is the best available treatment for patients with metastatic melanoma. In a recent series of three consecutive clinical trials using increasing lymphodepletion before infusion of autologous tumor infiltrating lymphocytes (TIL), objective response rates between 49% and 72% were seen. Persistence of infused cells in the circulation at one month was highly correlated with anti-tumor response as was the mean telomere length of the cells infused and the number of CD8+ CD27+ cells infused. Responses occur at all sites and appear to be durable with many patients in ongoing response beyond three years. In the most recent trial of 25 patients receiving maximum lymphodepletion, seven of the 25 patients (28%) achieved a complete response. Of the 12 patients in the three trials who achieved a complete response all but one are ongoing between 18 and 75 months. We recently demonstrated that ACT using autologous lymphocytes genetically modified to express anti-tumor T cell receptors can mediate tumor regression and this approach is now being applied to patients with common epithelial cancers.
Figures
Figure 1
Schema of the lymphodepleting preparative regimens used in the adoptive cell transfer protocols in the Surgery Branch, NCI.
Figure 2
Objective clinical regressions in patients with metastatic melanoma treated with cell transfer therapy. A. Regression of melanoma metastases in the heart (upper), adrenal (middle) and peritoneal cavity (lower) now ongoing at 34 months in a 53 year old male. B. Regression of multiple liver metastases now ongoing at 60 months in a 45 year old male. C. Rapid regression of multiple subcutaneous and nodal metastases now ongoing at 35 months in a 29 year old male. D. Regression of a large fungating scalp mass now ongoing at 34 months in a 40 year old male.
Figure 2
Objective clinical regressions in patients with metastatic melanoma treated with cell transfer therapy. A. Regression of melanoma metastases in the heart (upper), adrenal (middle) and peritoneal cavity (lower) now ongoing at 34 months in a 53 year old male. B. Regression of multiple liver metastases now ongoing at 60 months in a 45 year old male. C. Rapid regression of multiple subcutaneous and nodal metastases now ongoing at 35 months in a 29 year old male. D. Regression of a large fungating scalp mass now ongoing at 34 months in a 40 year old male.
Figure 2
Objective clinical regressions in patients with metastatic melanoma treated with cell transfer therapy. A. Regression of melanoma metastases in the heart (upper), adrenal (middle) and peritoneal cavity (lower) now ongoing at 34 months in a 53 year old male. B. Regression of multiple liver metastases now ongoing at 60 months in a 45 year old male. C. Rapid regression of multiple subcutaneous and nodal metastases now ongoing at 35 months in a 29 year old male. D. Regression of a large fungating scalp mass now ongoing at 34 months in a 40 year old male.
Figure 2
Objective clinical regressions in patients with metastatic melanoma treated with cell transfer therapy. A. Regression of melanoma metastases in the heart (upper), adrenal (middle) and peritoneal cavity (lower) now ongoing at 34 months in a 53 year old male. B. Regression of multiple liver metastases now ongoing at 60 months in a 45 year old male. C. Rapid regression of multiple subcutaneous and nodal metastases now ongoing at 35 months in a 29 year old male. D. Regression of a large fungating scalp mass now ongoing at 34 months in a 40 year old male.
Figure 3
Survival of patients treated with cell transfer therapy in four consecutive clinical trials using increasing regimens of a lymphodepleting preparative regimen prior to adoptive cell transfer (NMA, non-myeloablative chemotherapy; TBI, total body irradiation). The number in parentheses is the number of patients in each trial.
Figure 4
Objective response rates using RECIST criteria in patients with metastatic melanoma treated in the Surgery Branch, NCI using different therapeutic strategies. Overall response rates in patients treated with vaccines is about 3% and with IL-2 or anti-CTLA4 is about 15%. With increasing levels of lymphodepletion, adding total body irradiation (TBI) and nonmyeloablative chemotherapy (NMA) to adoptive cell transfer (ACT) can achieve response rates as high as 72%.
Figure 5
Schematic diagrams of the structure of retroviruses encoding conventional T cell receptors and chimeric T cell receptors prepared for use in adoptive cell transfer trials.
Similar articles
- CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA. Dudley ME, et al. Clin Cancer Res. 2010 Dec 15;16(24):6122-31. doi: 10.1158/1078-0432.CCR-10-1297. Epub 2010 Jul 28. Clin Cancer Res. 2010. PMID: 20668005 Free PMC article. Clinical Trial. - Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG. Hernandez-Chacon JA, et al. J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec. J Immunother. 2011. PMID: 21389874 Free PMC article. - Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME. Friedman KM, et al. J Immunother. 2012 Jun;35(5):400-8. doi: 10.1097/CJI.0b013e31825898c5. J Immunother. 2012. PMID: 22576345 Free PMC article. - Adoptive T-cell transfer in melanoma.
Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J, Besser MJ. Itzhaki O, et al. Immunotherapy. 2013 Jan;5(1):79-90. doi: 10.2217/imt.12.143. Immunotherapy. 2013. PMID: 23256800 Review. - Focus on adoptive T cell transfer trials in melanoma.
Hershkovitz L, Schachter J, Treves AJ, Besser MJ. Hershkovitz L, et al. Clin Dev Immunol. 2010;2010:260267. doi: 10.1155/2010/260267. Epub 2010 Dec 26. Clin Dev Immunol. 2010. PMID: 21234353 Free PMC article. Review.
Cited by
- Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.
Subhan MA, Torchilin VP. Subhan MA, et al. Bioengineering (Basel). 2024 Aug 14;11(8):830. doi: 10.3390/bioengineering11080830. Bioengineering (Basel). 2024. PMID: 39199788 Free PMC article. Review. - Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.
Castenmiller SM, Kanagasabesan N, Guislain A, Nicolet BP, van Loenen MM, Monkhorst K, Veenhof AAFA, Smit EF, Hartemink KJ, Haanen JBAG, de Groot R, Wolkers MC. Castenmiller SM, et al. Oncoimmunology. 2024 Aug 22;13(1):2392898. doi: 10.1080/2162402X.2024.2392898. eCollection 2024. Oncoimmunology. 2024. PMID: 39188755 Free PMC article. - Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy.
Knight AD, Luke JJ. Knight AD, et al. Curr Oncol Rep. 2024 Jul;26(7):826-839. doi: 10.1007/s11912-024-01551-4. Epub 2024 May 25. Curr Oncol Rep. 2024. PMID: 38789670 Review. - Surface-Functionalized Microgels as Artificial Antigen-Presenting Cells to Regulate Expansion of T Cells.
Lou J, Meyer C, Vitner EB, Adu-Berchie K, Dacus MT, Bovone G, Chen A, To T, Weitz DA, Mooney DJ. Lou J, et al. Adv Mater. 2024 Aug;36(31):e2309860. doi: 10.1002/adma.202309860. Epub 2024 May 29. Adv Mater. 2024. PMID: 38615189 - Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma.
Vargas GM, Shafique N, Xu X, Karakousis G. Vargas GM, et al. Expert Rev Mol Diagn. 2024 Apr;24(4):299-310. doi: 10.1080/14737159.2024.2312102. Epub 2024 Feb 5. Expert Rev Mol Diagn. 2024. PMID: 38314660 Free PMC article. Review.
References
- Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 1987;138:989–995. - PubMed
- Van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647. - PubMed
- Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10:281–287. - PubMed
- Dudley ME, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008;26:5233–5239. Three lymphodepleting regimens were combined with tumor reactive TIL administration and compared for safety and efficacy in sequential ACT clinical trials. Overall 52 of 93 patients (56%) experienced an objective response
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials